RESEARKA

Preclinical and disease-model investigations have generated plausible mechanistic links between PCSK9 inhibitors longevity and biological processes relevant to aging. Beyond lipid metabolism, PCSK9 modulation has been associated with inflammatory signaling pathways: in human aortic endothelial cells, evolocumab treatment attenuated IL-6-driven inflammatory responses through mechanisms involving SIRT3-mediated effects on autophagy and oxidative stress (Donofrio 2023). Furthermore, clinical studies have documented that PCSK9 inhibitors longevity possess apolipoprotein C-III-related anti-inflammatory activity, as assessed by glycoprotein profiling in high cardiovascular risk patients (Rehues 2023). These generated biomedical observations collectively suggest that the PCSK9 inhibitors longevity mechanism may extend beyond LDL-C lowering to modulate vascular inflammation and endothelial function, although the translation of these mechanistic signals to clinically meaningful longevity endpoints remains incompletely characterized.

Citation Support

• source_1 Ma 2025
• source_2 Schwartz 2021
• source_3 Lehrke 2024
• source_4 Imran 2023
• source_5 Faraidy 2023